GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Melbourne-based biotech VC Boson Ventures has raised $10 million of a target $30 million fund and is positioning itself as a ...

Asian equities were mostly lower overnight on increased trade rhetoric and the hiking of tariffs on Canada and a litany of ...

Colorectal cancer patients could soon have access via the NHS to a targeted oral drug that can give them more precious time with their loved ones.

AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso ...